Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 205409. Отображено 100.
05-01-2012 дата публикации

Recombinant fusion protein and polynucleotide construct for immunotoxin production

Номер: US20120003223A1
Автор: Itai Benhar, Yariv Mazor
Принадлежит: Ramot at Tel Aviv University Ltd

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III)

Номер: US20120003240A1
Автор: Hanna-Riikka Honkanen, Heikki Hyöty, Jeffrey Almond, Malin Flodström-Tullberg, Mikael Knip, Minna Pulkki, Olli Laitinen, Outi Tolonen, Sami Oikarinen, Valerie Lecouturier
Принадлежит: Sanofi Pasteur Inc, Vactech OY

Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.

Подробнее
Номер записи: 2
05-01-2012 дата публикации

Immunogenic compositions for inducing an immune response to hiv

Номер: US20120003265A1
Автор: John H. Eldridge, Maninder K. Sidhu, Michael Egan, Zimra Israel
Принадлежит: WYETH LLC

The invention relates to immunogenic compositions for inducing an immune response to HIV comprising combinations of two, three, or four plasmids, where each plasmid is expressing a defined antigen, which may be a single antigen or a fusion of two or three antigens.

Подробнее
Номер записи: 3
05-01-2012 дата публикации

Compositions Produced Using Enteric Pathogens and Methods of Use

Номер: US20120003269A1
Автор: Darren E. Straub, Daryll A. Emery, Laura Wonderling
Принадлежит: Epitopix LLC

The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella . Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.

Подробнее
Номер записи: 4
05-01-2012 дата публикации

High affinity antibodies to human il-6 receptor

Номер: US20120003697A1
Автор: Ashique Rafique, Eric Smith, Gang Chen, James P. Fandl, Jeanette L. Fairhurst, Joel H. Martin, Kevin J. Pobursky, Margaret Karow, Nicholas J. Papadopoulos, Sean Stevens, Tammy T. Huang
Принадлежит: Regeneron Pharmaceuticals Inc

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K D of about 500 pM or less and blocks IL-6 activity with an IC 50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

Подробнее
Номер записи: 5
12-01-2012 дата публикации

ANTI-Aß OLIGOMER HUMANIZED ANTIBODY

Номер: US20120009179A1
Автор: Nobuyuki SUZUKI, Tsuguo Kubota
Принадлежит: Kyowa Hakko Kirin Co Ltd

An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

Подробнее
Номер записи: 6
12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1
Автор: Anton Mayr, Barbara Mayr
Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее
Номер записи: 7
12-01-2012 дата публикации

Transfection of blood cells with mrna for immune stimulation and gene therapy

Номер: US20120009221A1
Автор: Florian Van Der Mülbe, Ingmar Hoerr, Steve Pascolo
Принадлежит: CureVac AG

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

Подробнее
Номер записи: 8
12-01-2012 дата публикации

Modulation of the immune response

Номер: US20120009222A1
Автор: Daniel Griffith Anderson, David-Huy Nhu Nguyen, Kerry Peter Mahon, Robert S. Langer
Принадлежит: Massachusetts Institute of Technology

The present invention provides lipidoids that can be used to modulate the immune response in a subject. Lipidoids are prepared by the conjugate addition of an amine to an acrylate to acrylamide. The lipidoids form complexes or particles with an immunostimulatory polynucleotide, which are then administerd to a subject. Such compositions have been found to stimulate the production of cytokines and increase both humoral and cell-mediate immune response. The invention also provides pharmaceuti-cal compositions thereof and methods for using the same.

Подробнее
Номер записи: 9
12-01-2012 дата публикации

Respiratory Syncytial Virus Antigenic Compositions and Methods

Номер: US20120009254A1
Автор: James Gorham Boyd, Thomas J. Powell
Принадлежит: Artificial Cell Technologies Inc

Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response.

Подробнее
Номер записи: 10
19-01-2012 дата публикации

Il-1beta binding antibodies and fragments thereof

Номер: US20120014967A1
Автор: Arnold Horwitz, Gang Chen, Linda Masat, Marina Roell, Mary Haak-Frendscho
Принадлежит: Xoma Technology Ltd USA

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Подробнее
Номер записи: 11
19-01-2012 дата публикации

Avirulent, immunogenic flavivirus chimeras

Номер: US20120014981A1
Автор: Claire Y.H. Kinney, Duane J. Gubler, Natth Bhamarapravati, Richard M. Kinney, Siritorn Butrapet
Принадлежит: Centers of Disease Control and Prevention CDC, Mahidol University, US Department of Health and Human Services

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

Подробнее
Номер записи: 12
19-01-2012 дата публикации

Dna vaccine for alzheimer's disease

Номер: US20120014987A1
Автор: Yoh Matsumoto
Принадлежит: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE

The present invention aims to provide a DNA vaccine for Alzheimer's disease. The present invention provides a recombinant vector which comprises DNA encoding amyloid β and DNA encoding a Th2 cytokine, as well as a DNA vaccine for Alzheimer's disease which comprises this vector.

Подробнее
Номер записи: 13
19-01-2012 дата публикации

Estrogen receptors and methods of use

Номер: US20120016109A1
Автор: Zhao Yi Wang
Принадлежит: CREIGHTON UNIVERSITY

The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.

Подробнее
Номер записи: 14
26-01-2012 дата публикации

Antibodies against fatty acid synthase

Номер: US20120020978A1
Автор: Patrick J. Muraca
Принадлежит: Nuclea Biotechnologies Inc

The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.

Подробнее
Номер записи: 15
26-01-2012 дата публикации

Vaccine

Номер: US20120020993A1
Автор: Joann Lisa Prior, Rachel Elizabeth Dean, Sarah Victoria Harding, Timothy Phillip Atkins
Принадлежит: UK Secretary of State for Defence

The present invention relates to a pharmaceutical formulation comprising lipopolysaccharide derived from Burkholderia thailandensis and its various uses, including but not limited to its use in the treatment and/or prophylaxis of meliodosis or amelioration of symptoms associated therewith, and/or glanders or amelioration of symptoms associated therewith.

Подробнее
Номер записи: 16
26-01-2012 дата публикации

Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof

Номер: US20120021002A1
Автор: Konstantin Ichtchenko, Philip A. Band
Принадлежит: New York University NYU

The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.

Подробнее
Номер записи: 17
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
Номер записи: 18
02-02-2012 дата публикации

Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers

Номер: US20120027779A1
Автор: Camille Grandclement, Christophe Borg, John Wijdenes
Принадлежит: Diaclone SAS, EFS Bourgogne Franche Comte, Université de Franche-Comté

The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment.

Подробнее
Номер записи: 19
02-02-2012 дата публикации

Immunological herpes simplex virus antigens and methods for use thereof

Номер: US20120027790A1
Автор: David M. Koelle, Lawrence Corey
Принадлежит: UNIVERSITY OF WASHINGTON

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Подробнее
Номер записи: 20
02-02-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120027796A1
Автор: David Butler, Jayaprakash K. Narayanannair, Kallanthottathil G. Rajeev, Laxmab Eltepu, Muthiah Manoharan, Muthusamy Jayaraman
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).

Подробнее
Номер записи: 21
02-02-2012 дата публикации

Antibody gene transfer and recombinant aav therefor

Номер: US20120027798A1
Автор: Kelly Reed Clark, Philip R. Johnson, Jr.
Принадлежит: Nationwide Childrens Hospital Inc

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Подробнее
Номер записи: 22
02-02-2012 дата публикации

Posterior segment drug delivery

Номер: US20120029470A1
Автор: Cary J. Reich, Douglas Sutton, Eugene de Juan, Jr., Hanson S. Gifford, Iii, K. Angela Macfarlane, Kathleen Cogan Farinas, Michael Barrett, Randolph E. Campbell, Yair Alster
Принадлежит: ForSight Vision4 Inc

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Подробнее
Номер записи: 23
09-02-2012 дата публикации

Artificial cells

Номер: US20120034155A1
Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne R. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
Номер записи: 24
09-02-2012 дата публикации

Artificial cells

Номер: US20120034157A1
Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne A. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
Номер записи: 25
09-02-2012 дата публикации

Method of Administering an Antibody

Номер: US20120034243A1
Автор: David Edward Allison, Judith A. Fox, Lee R. Brettman
Принадлежит: Genentech Inc, Millennium Pharmaceuticals Inc

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

Подробнее
Номер записи: 26
09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1
Автор: Alessandro FATATIS, Nathan Graeme DOLLOFF, Nick LOIZOS
Принадлежит: ImClone LLC, Philadelphia Health and Education Corp

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее
Номер записи: 27
09-02-2012 дата публикации

Influenza Vaccines, Antigens, Compositions, and Methods

Номер: US20120034253A1
Автор: Konstantin Musiychuk, Vadim Mett, Vidadi Yusibov
Принадлежит: Fraunhofer USA Inc

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, compositions, and methods for the production of such antigens in plants. In some embodiments, influenza antigens include hemagglutinin polypeptides, neuraminidase polypeptides, and/or combinations thereof.

Подробнее
Номер записи: 28
09-02-2012 дата публикации

Vaccine

Номер: US20120036589A1
Автор: Alexandra Adams, Kim Thompson, Saravanane Poobalane
Принадлежит: University of Stirling

The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.

Подробнее
Номер записи: 29
16-02-2012 дата публикации

Methods of treating pain

Номер: US20120039866A1
Автор: Daniela Salvemini
Принадлежит: St Louis University

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

Подробнее
Номер записи: 30
16-02-2012 дата публикации

Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Номер: US20120039874A1
Автор: Katsunari Tezuka, Nobuaki Hori, Takashi Tsuji
Принадлежит: Japan Tobacco Inc

Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Подробнее
Номер записи: 31
16-02-2012 дата публикации

Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-b-amyloid antibody

Номер: US20120039897A1
Автор: Marilena Manea, Michael Bacher, Michael Przybylski, Raluca Stefanescu, Richard Dodel
Принадлежит: Philipps Universitaet Marburg

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Подробнее
Номер записи: 32
16-02-2012 дата публикации

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

Номер: US20120039899A1
Автор: Andres G. Grandea, III, Christina L. Boozer, Ole Olsen
Принадлежит: Theraclone Sciences Inc

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Подробнее
Номер записи: 33
16-02-2012 дата публикации

Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Номер: US20120039916A1
Автор: Anne-Laure Flamar, Gérard ZURAWSKI, Jacques F. Banchereau
Принадлежит: BAYLOR RESEARCH INSTITUTE

Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.

Подробнее
Номер записи: 34
16-02-2012 дата публикации

Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Номер: US20120039936A1
Автор: Paul Howley, Sonja Leyrer
Принадлежит: Individual

The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.

Подробнее
Номер записи: 35
16-02-2012 дата публикации

Compositions and methods for vaccine and virus production

Номер: US20120039939A1
Автор: Chia Chu, Joseph Shiloach, Michael Betenbaugh, Pratik Jaluria
Принадлежит: JOHNS HOPKINS UNIVERSITY

The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.

Подробнее
Номер записи: 36
16-02-2012 дата публикации

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

Номер: US20120040010A1
Автор: Brian Carpenter, Moti Harel
Принадлежит: Individual

The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

Подробнее
Номер записи: 37
16-02-2012 дата публикации

Method of detecting progression of a neurodementing disease

Номер: US20120040382A1
Автор: Marilena Manea, Michael Bacher, Michael Przybylski, Raluca Stefanescu, Richard Dodel
Принадлежит: Philipps Universitaet Marburg

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Подробнее
Номер записи: 38
23-02-2012 дата публикации

Human papilloma virus peptide-specific T-cell response for treatment of warts

Номер: US20120045413A1
Автор: Kevin Kim, Mayumi Nakagawa, Thomas Horn
Принадлежит: Kevin Kim, Mayumi Nakagawa, Thomas Horn

The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) found in and causing the warts. It was found that the patients showed a response to HPV type 57 L1 peptide 380-412 (a peptide consisting of amino acid residues 380-412 of the protein L1) and HPV type 57 protein E4 (E4 10-30). One embodiment of the invention provides a pharmaceutical composition comprising a polypeptide comprising (a) L1 380-412 (SEQ ID NO:3) or a fragment of at least 8 residues of SEQ ID NO:3 or (b) E4 10-30 (SEQ ID NO:4) or a fragment of at least 8 residues of E4 10-30 (SEQ ID NO:4), wherein the composition is immunogenic in humans.

Подробнее
Номер записи: 39
23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1
Автор: Alexey V. Teplyakov, Ellen Chi, Gopalan Raghunathan, Hong Mimi Zhou, Jill Giles-Komar, Jill M. Carton, Johan Fransson, Juan C. Almagro, Karyn T. O'neil, Linus Hyun, Ronald V. Swanson, Shanrong Zhao, Wendy Cordier, Yiqing Feng
Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее
Номер записи: 40
23-02-2012 дата публикации

Human monoclonal antibodies to ctla-4

Номер: US20120045442A1
Автор: C. Geoffrey Davis, Douglas Charles Hanson, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Jose Ramon Corvalan, Mark Joseph Neveu, Steven Christopher Gilman
Принадлежит: Abgenix Inc, PFIZER INC

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Подробнее
Номер записи: 41
23-02-2012 дата публикации

Stabilized anti-respiratory syncytial virus (rsv) antibody formulations

Номер: US20120045456A1
Автор: Christian B. Allan, Cynthia N. Oliver, Stephen T. Chang
Принадлежит: MEDIMMUNE LLC

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

Подробнее
Номер записи: 42
23-02-2012 дата публикации

Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof

Номер: US20120045464A1
Автор: J. Neil Simonsen
Принадлежит: Individual

Cloning and expression of genes encoding C. parvum antigenic polypeptides are described as are antibodies that recognize epitopes on these polypeptides. The antigenic polypeptides and antibodies thereto can be used in therapeutic compositions for the prevention and treatment of C. parvum infections, as well as in diagnostic methods for determining the presence of C. parvum infections.

Подробнее
Номер записи: 43
23-02-2012 дата публикации

Biomolecule Surface Display and Uses Thereof

Номер: US20120045473A1
Автор: Jimmy Kwang
Принадлежит: Temasek Life Sciences Laboratory Ltd

A vaccine for the treatment or prevention of a disease in a subject, wherein said disease is associated with an avian influenza virus, and wherein said vaccine comprises an expression vector comprising a nucleic acid encoding a hemagglutinin peptide, such that in use said hemagglutinin peptide is expressed by said expression vector in said subject.

Подробнее
Номер записи: 44
23-02-2012 дата публикации

Thermosensitive hepatitis b vaccine

Номер: US20120045511A1
Автор: Ho-Yuan Chou, Hsin-Hsin Shen, Mi-Hua Tao, Tsai-Yu Lin
Принадлежит: Industrial Technology Research Institute ITRI

A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness.

Подробнее
Номер записи: 45
23-02-2012 дата публикации

TREATMENT OF CELIAC DISEASE WITH IgA

Номер: US20120045517A1
Автор: Mark Andrew Kroenke, Michael Richard Simon
Принадлежит: Individual

A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

Подробнее
Номер записи: 46
23-02-2012 дата публикации

ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

Номер: US20120046451A1
Автор: Akihiko Takasaki, Atsushi Sugioka, Chiho Muramatsu, Gene Kurosawa, Kazuhiro Morishita, Kazuhiro Suzuki, Kazuki Matsuda, Keiko Ogawa, Mariko Sumitomo, Masachika Azuma, Miwa Morita, Nobuhiro Hayashi, Nobuhiro Takahashi, Sari Fujiyama, Susumu Tsutsumi, Yasushi Akahori, Yoshikazu Kurosawa, Yoshinori Ukai, Yoshitaka Iba
Принадлежит: Institute for Antibodies Co Ltd

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Подробнее
Номер записи: 47
01-03-2012 дата публикации

Vaccine composition for prophylaxis and/or therapy of alzheimer's disease

Номер: US20120052086A1
Автор: Atsushi Takahashi, Hisakazu Hasegawa, Mikio Shoji, Takeshi Kawarabayashi, Teruhiko Terakawa, Yasushi Shimada
Принадлежит: Hokko Chemical Industry Co Ltd

A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.

Подробнее
Номер записи: 48
01-03-2012 дата публикации

Immunogenic epitopes of ngep antigen

Номер: US20120052116A1
Автор: Ira Pastan, Jeffrey Schlom, Kwong-Yok Tsang
Принадлежит: US Department of Health and Human Services

The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Подробнее
Номер записи: 49
01-03-2012 дата публикации

Anti-vegf-c antibodies and methods using same

Номер: US20120052566A9
Автор: Anil D. Bagri, Chingwei V. Lee, Germaine Fuh
Принадлежит: F Hoffmann La Roche AG

The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.

Подробнее
Номер записи: 50
01-03-2012 дата публикации

ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN TUMOR SUPPRESSING SUBTRANSFERABLE CANDIDATE 4 (TSSC4)

Номер: US20120053232A1
Автор: James W. Ryan
Принадлежит: RYOGEN LLC

Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.

Подробнее
Номер записи: 51
08-03-2012 дата публикации

Anti- integrin antibodies, compositions, methods and uses

Номер: US20120058128A1
Автор: Jill Giles-Komar, Linda Snyder, Marian T. Nakada, Mohit Trikha
Принадлежит: Janssen Biotech Inc

The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Подробнее
Номер записи: 52
08-03-2012 дата публикации

Purified Plasmodium and Vaccine Compositions

Номер: US20120058543A1
Автор: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
Принадлежит: Sanaria Inc

Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.

Подробнее
Номер записи: 53
08-03-2012 дата публикации

Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved

Номер: US20120058572A1
Автор: Naruto Katsuragi, Ryuichi Morishita, Yoshiaki Taniyama
Принадлежит: Daiichi Sankyo Co Ltd, Osaka University NUC

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

Подробнее
Номер записи: 54
15-03-2012 дата публикации

Method for Treating Psoriatic Arthritis by Administering an Anti-IL-12 Antibody

Номер: US20120063998A1
Автор: Bemard Scallon, David M. Knight, David Peritt, David Shealy, Jill Giles-Komar
Принадлежит: Individual

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.

Подробнее
Номер записи: 55
15-03-2012 дата публикации

Psca: prostate stem cell antigen and uses thereof

Номер: US20120063999A1
Автор: Aya Jakobovitz, Douglas C. Saffran, Owen N. Witte, Robert E. Reiter
Принадлежит: Agensys Inc, UNIVERSITY OF CALIFORNIA

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Подробнее
Номер записи: 56
15-03-2012 дата публикации

Monoclonal Antibodies to Hepatocyte Growth Factor

Номер: US20120064066A1
Автор: Kyung Jin Kim, Yi-Chi Su
Принадлежит: Galaxy Biotech LLC

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Подробнее
Номер записи: 57
15-03-2012 дата публикации

Therapeutic use of anti-cs1 antibodies

Номер: US20120064083A1
Автор: Gao Liu, J. Yun Tso, Marna Williams, Nicholas F. Landolfi
Принадлежит: Abbott Biotherapeutics Corp

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Подробнее
Номер записи: 58
15-03-2012 дата публикации

Tetravalent influenza vaccine and use thereof

Номер: US20120064117A1
Автор: Hairong Lu, Ted M. Ross, Xianchun Tang
Принадлежит: University of Pittsburgh

Disclosed herein is the finding that baculovirus display of multiple influenza virus hemagglutinin (HA) proteins elicits broadly reactive immune responses against influenza. Thus provided herein are recombinant baculovirus vectors having a first, second, third and fourth nucleic acid sequence, each encoding an influenza hemagglutinin (HA) fusion protein. The first, second, third and fourth nucleic acid sequences each encode an influenza HA with a different amino acid sequence. Also provided are recombinant baculoviruses displaying a first, second, third and fourth influenza virus HA fusion protein in the baculovirus envelope, wherein each HA fusion protein comprises a different HA amino acid sequence. Tetravalent influenza virus vaccines comprising the recombinant baculoviruses disclosed herein are further provided. In addition, methods of immunizing a subject against influenza virus using the tetravalent influenza virus vaccines are provided. In particular examples of the compositions and methods disclosed herein, the HA polypeptides are from H5N1 influenza virus.

Подробнее
Номер записи: 59
15-03-2012 дата публикации

Test agent for visceral obesity and use thereof

Номер: US20120066777A1
Автор: Atsunori Kashiwagi, Hiroshi Maegawa, Masatomo Rokushima, Minoru Ikeda, Minoru Suzuki, Shiro Maeda, Tatsuya Takahashi, Tohru Tani, Yoshihiro Kawamura
Принадлежит: RIKEN Institute of Physical and Chemical Research, Shiga University of Medical Science NUC, Shionogi and Co Ltd

Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.

Подробнее
Номер записи: 60
22-03-2012 дата публикации

Treatment of vascularized pigment epithelial detachment with anti-vegf therapy

Номер: US20120070428A1
Автор: Clement K. Chan, Prema Abraham
Принадлежит: Genentech Inc

Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed.

Подробнее
Номер записи: 61
22-03-2012 дата публикации

Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof

Номер: US20120070429A1
Автор: Leslie S. Johnson, Ling Huang
Принадлежит: Macrogenics Inc

The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Подробнее
Номер записи: 62
22-03-2012 дата публикации

Targeted multi-epitope dosage forms for induction of an immune response to antigens

Номер: US20120070493A1
Автор: Christopher Fraser, David H. Altreuter, Grayson B. Lipford
Принадлежит: Selecta Biosciences Inc

Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.

Подробнее
Номер записи: 63
22-03-2012 дата публикации

Prevention and treatment of blood coagulation-related disases

Номер: US20120073002A1
Автор: Hiroyuki Saito, Kazutaka Yoshihashi, Kunihiro Hattori, Takehisa Kitazawa
Принадлежит: Chugai Pharmaceutical Co Ltd

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Подробнее
Номер записи: 64
29-03-2012 дата публикации

Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof

Номер: US20120076806A1
Автор: Andrew R. Mendelsohn, James Larrick, Keith N. Haffer
Принадлежит: BRAASCH BIOTECH LLC

Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.

Подробнее
Номер записи: 65
29-03-2012 дата публикации

Novel malaria vaccine

Номер: US20120076816A1
Автор: Ken Ishii, Takahiro Tougan, Toshihiro Horii
Принадлежит: Osaka University NUC

The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X 1 -A-B-X 2 -Y-X 3 -(Y)n-X 4 -(Y)n-X 5   (1) (In the formula, X 1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X 2 represents the 73th to 177th amino acid residues; X 3 represents the 178th to 258th amino acid residues; X 4 represents the 259th to 289th amino acid residues; X 5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum ; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum ; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.)

Подробнее
Номер записи: 66
05-04-2012 дата публикации

Soluble il-17ra/rc fusion proteins and related methods

Номер: US20120082668A1
Автор: Gao Zeren, Mark W. Rixon, Steven D. Levin
Принадлежит: Zymogenetics Inc

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Подробнее
Номер записи: 67
05-04-2012 дата публикации

Method of Producing Rough Strains of Bacteria and Uses Thereof

Номер: US20120082699A1
Автор: Cynthia Ann Stanford, Graham Mcintyre, John Lawson Stanford, Oscar Adelmo Bottasso
Принадлежит: Bioeos Ltd

The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense , said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4′-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.

Подробнее
Номер записи: 68
05-04-2012 дата публикации

Myostatin binding agents

Номер: US20120083442A1
Автор: Hosung Min, Hq Han, Thomas Charles Boone
Принадлежит: AMGEN INC

The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

Подробнее
Номер записи: 69
12-04-2012 дата публикации

Immunotherapeutic agent

Номер: US20120087900A1
Автор: Tai-Gyu Kim
Принадлежит: Industry Academic Cooperation Foundation of Catholic University of Korea

The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.

Подробнее
Номер записи: 70
19-04-2012 дата публикации

Process for producing poxviruses and poxvirus compositions

Номер: US20120093780A1
Автор: Claude Sene, Daniel Malarme, Yves Cordier
Принадлежит: TRANSGENE SA

The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.

Подробнее
Номер записи: 71
19-04-2012 дата публикации

Anti-vegf-d antibodies

Номер: US20120093811A1
Автор: Andrew J. Pow, George Kopsidas, Irene Koukoulas, Jason W. Simmonds, Vincent Emil W. Batori
Принадлежит: Vegenics Pty Ltd

The invention relates to an isolated antibody that specifically binds vascular endothelial growth factor-D (VEGF-D) and to a humanized antibody that specifically binds VEGF-D.

Подробнее
Номер записи: 72
19-04-2012 дата публикации

Non-lipidated variants of neisseria meningitidis orf2086 antigens

Номер: US20120093852A1
Автор: Annaliesa Sybil Anderson, Justin Keith Moran, Kathrin Ute Jansen, Mark E. Ruppen, Susan Kay Hoiseth
Принадлежит: WYETH LLC

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis , and methods related thereto.

Подробнее
Номер записи: 73
19-04-2012 дата публикации

RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF

Номер: US20120093855A1
Автор: Joel R. Haynes
Принадлежит: Ligocyte Pharmaceuticals Inc

The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems.

Подробнее
Номер записи: 74
19-04-2012 дата публикации

Tat-Based Tolerogen Compositions and Methods for Making and Using Same

Номер: US20120093858A1
Автор: David I. Cohen
Принадлежит: PIN Pharma Inc

A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided.

Подробнее
Номер записи: 75
19-04-2012 дата публикации

Influenza vaccine regimens for pandemic-associated strains

Номер: US20120093859A1
Автор: Elena Fragapane, Nicola Groth
Принадлежит: NOVARTIS AG

In contrast to known regimens where pandemic-associated antigens are given 3-4 weeks apart for immunisation, according to the invention two doses of a pandemic-associated antigen are administered to a human 1 week apart, 2 weeks apart or 6 weeks apart. Thus the invention provides a method for immunizing a human, comprising steps of: (a) administering to the human a first vaccine comprising antigen from a pandemic-associated influenza virus strain; and then 1/2/6 week(s) later, (b) administering to the same human a second influenza vaccine comprising antigen from the pandemic-associated influenza virus strain.

Подробнее
Номер записи: 76
19-04-2012 дата публикации

Influenza vaccines with increased amounts of h3 antigen

Номер: US20120093860A1
Автор: Klaus Stohr, Theodore Tsai
Принадлежит: NOVARTIS AG

An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from an A/H1N1 strain, an A/H3N2 strain, and a B strain, wherein (i) the weight ratio of H3N2:H1N1 hemagglutinin is greater than 1 and (ii) the weight ratio of H3N2:B hemagglutinin is greater than 1. In such a vaccine the weight ratio of H1N1:B hemagglutinin will normally be 1. For example, a vaccine may contain hemagglutinin at 15 μg for A/H1N1, 30 μg for A/H3N2 and 15 μg for B.

Подробнее
Номер записи: 77
19-04-2012 дата публикации

Hcv vaccines and methods for using the same

Номер: US20120093863A1
Автор: Amir S. Khan, David B. Weiner, Jian Yan, Krystle LANG, Ruxandra Draghia-Akli
Принадлежит: Inovio Pharmaceuticals Inc, University of Pennsylvania Penn

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Подробнее
Номер записи: 78
19-04-2012 дата публикации

GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis

Номер: US20120093867A1
Автор: Dan M. Granoff, Victor Chen-Hsi Hou
Принадлежит: Individual

The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.

Подробнее
Номер записи: 79
19-04-2012 дата публикации

Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis

Номер: US20120094950A1
Автор: Javier Ochoa-Reparaz, Lloyd H. Kasper
Принадлежит: Dartmouth College

The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.

Подробнее
Номер записи: 80
19-04-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120095075A1
Автор: David Butler, Kallanthottathil G. Rajeev, Laxman Eltepu, Muthiah Manoharan, Muthusamy Jayaraman, Narayanannair K. Jayaprakash
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure:

Подробнее
Номер записи: 81
26-04-2012 дата публикации

Use of anti-cd20 antibody for treating primary intraocular lymphoma

Номер: US20120100133A1
Автор: Catherine Fridman, Remi Urbain, Sylvain Fisson
Принадлежит: LFB Biotechnologies SAS

An embodiment relates to a monoclonal antibody directed against the CD20 antgen, in which the variable region of each of the light chains is coded by murine nucleic acid sequence SEQ ID NO:1, the variable region of each of the heavy chains is coded by murine nucleic acid sequence SEQ ID NO: 2, and the constant regions of the light chains and of the heavy chains originate from a non-murine species, said antibody being used for treating primary intraocular lymphoma.

Подробнее
Номер записи: 82
26-04-2012 дата публикации

CD86 Antagonist Multi-Target Binding Proteins

Номер: US20120100139A1
Автор: John W. Blankenship, Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, Sateesh Kumar Natarajan
Принадлежит: Emergent Product Development Seattle LLC

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Подробнее
Номер записи: 83
26-04-2012 дата публикации

Anti-human cd52 immunoglobulins

Номер: US20120100152A1
Автор: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
Принадлежит: Genzyme Corp

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Подробнее
Номер записи: 84
26-04-2012 дата публикации

Continuous Cell Programming Devices

Номер: US20120100182A1
Автор: David J. Mooney, Glenn Dranoff, Omar Ali
Принадлежит: Individual

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

Подробнее
Номер записи: 85
26-04-2012 дата публикации

Antibodies having altered effector function and methods for making the same

Номер: US20120100575A1
Автор: Ellen Garber, Frederick R. Taylor
Принадлежит: BIOGEN IDEC MA INC

The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Подробнее
Номер записи: 86
26-04-2012 дата публикации

Compositions and methods for biological remodeling with frozen particle compositions

Номер: US20120101738A1
Автор: Daniel B. Cook, Edward S. Boyden, Elizabeth A. Sweeney, Eric C. Leuthardt, Lowell L. Wood, JR., Nathan P. Myhrvold, Roderick A. Hyde
Принадлежит: SEARETE LLC

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Подробнее
Номер записи: 87
03-05-2012 дата публикации

Synthetic Oligopeptides Designed From Mite Cysteine Proteases and Methods for the Production of

Номер: US20120107335A1
Автор: Catalina Sosa, Dary Luz Mendoza, Eduardo Egea, Elkin Navarro, Gloria Garavito, Johana Espejo, Luis Alejandro Barrera
Принадлежит: Fundacion Universidad del Norte Co, PONTIFICIA UNIVERSIDAD JAVERIANA

The invention refers to the design, synthesis and evaluation of 6 synthetic oligopeptides, that have not been previously described, designed from the T and B epitopes of allergens of group I of intradomiciliary mites of the species Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis , which can be used in the immunomodulation of individuals having immunocompetent systems and in the production of IgY polyclonal antibodies. The invention relates to a first method for obtaining a composition of IgY polyclonal antibodies that can be used as a diagnostic reagent having low cost and high reactivity in respect of intradomiciliary mites, and a second method for the detection of mite allergens, using the IgY antibody composition developed in the first method. The invention further relates to the composition of the IgY polyclonal antibodies.

Подробнее
Номер записи: 88
03-05-2012 дата публикации

Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method

Номер: US20120107342A1
Автор: Bernard Adri Bokhout, Florine Johanna Van Milligen, Johannes Bernardus Wilhelmus Joseph Cornelissen
Принадлежит: Stichting Dienst Landbouwkundig Onderzoek DLO

Described is an ex vivo animal or challenge model used as a method to identify protective (e.g., recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. Further described are vaccines directed against infection with parasites, such as Fasciola hepatica , which vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. Further described are protective (e.g., recombinant) proteins obtained from newly excysted juveniles (NEJ) of F. hepatica . The protective (recombinant) protein corresponding to an NEJ protein has an apparent molecular weight of 32 kD and an N-terminal amino acid molecule comprising the sequence XXDVSWPFWDRMYNY (SEQ ID NO:1).

Подробнее
Номер записи: 89
03-05-2012 дата публикации

Manufacture of vaccines that contain both hepatitis b virus surface antigens and surfactant

Номер: US20120107345A1
Автор: Mario Contorni
Принадлежит: Individual

When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.

Подробнее
Номер записи: 90
03-05-2012 дата публикации

Multivalent pcv2 immunogenic compositions and methods of producing such compositions

Номер: US20120107348A1
Автор: Greg Nitzel, Marc Eichmeyer, Michael Roof, Phillip Hayes
Принадлежит: Boehringer Ingelheim Vetmedica Inc

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine,

Подробнее
Номер записи: 91
03-05-2012 дата публикации

Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians

Номер: US20120107352A1
Автор: Juan Ignacio Ovejero Guisasola, Manuel Fresno Escudero
Принадлежит: Individual

The present invention relates to the isolation, purification and characterization of the Lipopolysaccharide (LPS) from Ochrobactrum intermedium strain LMG3306, and their use as immunostimulant of mammalians, the process for the preparation of a pharmaceutical compound for the treatment and/or prevention of the sepsis and adjuvant for a vaccine in immunosupressed animals and against Leishmania.

Подробнее
Номер записи: 92
03-05-2012 дата публикации

Composition useful as rotavirus vaccine and a method therefor

Номер: US20120107356A1
Автор: Krishna Mohan Vadrevu, Sai Devarajulu Prasad, Selvi Veerabadran
Принадлежит: Bharat Biotech International Ltd

Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.

Подробнее
Номер записи: 93
03-05-2012 дата публикации

Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same

Номер: US20120107910A1
Автор: George Dacai Liu
Принадлежит: Individual

The present invention provides a recombinant HIV Env antigenic protein, a virus-like particle and a recombinant HIV virus. The present invention further provides a vaccine comprising the recombinant HIV Env antigenic protein, the virus-like particle or recombinant HIV virus.

Подробнее
Номер записи: 94
03-05-2012 дата публикации

Recombinant il-9 antibodies and uses thereof

Номер: US20120109097A1
Автор: Herren Wu, Jeffry D. Watkins, Jennifer Lynne Reed, Julian Davies, Ying Tang
Принадлежит: MEDIMMUNE LLC

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Подробнее
Номер записи: 95
10-05-2012 дата публикации

Method for treating immune disorders

Номер: US20120114555A1
Автор: Andrew T. Hutchinson, Darren R. Jones, Parisa Asvadi, Robert L. Raison, Rosanne D. Dunn
Принадлежит: IMMUNE SYSTEM THERAPEUTICS LTD

The present invention relates to the treatment of B-cell mediated immune disorders such as rheumatoid arthritis, systemic lupus erythromatomus, diabetes mellitus, and multiple sclerosis. In particular, the present invention relates to the treatment of B-cell mediated immune disorders using antibodies which bind to membrane-bound free light chain expressed on the surface of plasma cell precursors.

Подробнее
Номер записи: 96
10-05-2012 дата публикации

Tslp promotes immune evasion and persistence of viruses

Номер: US20120114596A1
Автор: Bernhard Homey, Isabel Fernandez, Vassili Soumelis
Принадлежит: HEINRICH-HEINE-UNIVERSITAET, INSTITUT CURIE, Institut National de la Sante et de la Recherche Medicale INSERM

It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.

Подробнее
Номер записи: 97
10-05-2012 дата публикации

Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities

Номер: US20120114603A1
Автор: Grant F. Gallagher, Sergei Kotenko
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Подробнее
Номер записи: 98
10-05-2012 дата публикации

Single chain antibodies against beta-amyloid peptide

Номер: US20120114650A1
Автор: Beka Solomon, Rachel Cohen-Kupiec
Принадлежит: Ramot at Tel Aviv University Ltd

Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Aβp 1-40 and disaggregate Aβp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-AβP scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.

Подробнее
Номер записи: 99
10-05-2012 дата публикации

Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Номер: US20120114671A1
Автор: Joan Seoane Suarez, José BASELGA TORRES, Silvia Penuelas Prieto
Принадлежит: Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR, Institucio Catalana de Recerca i Estudis Avancats ICREA

The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

Подробнее
Номер записи: 100